89 related articles for article (PubMed ID: 23129363)
41. Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer.
Suárez J; Vera R; Balén E; Gómez M; Arias F; Lera JM; Herrera J; Zazpe C
Colorectal Dis; 2008 Jul; 10(6):563-8. PubMed ID: 18070184
[TBL] [Abstract][Full Text] [Related]
42. Mandard tumour regression grade, perineural invasion, circumferential resection margin and post-chemoradiation nodal status strongly predict outcome in locally advanced rectal cancer treated with preoperative chemoradiotherapy.
Dhadda AS; Bessell EM; Scholefield J; Dickinson P; Zaitoun AM
Clin Oncol (R Coll Radiol); 2014 Apr; 26(4):197-202. PubMed ID: 24485884
[TBL] [Abstract][Full Text] [Related]
43. A circumferential resection margin of 1 mm is a negative prognostic factor in rectal cancer patients with and without neoadjuvant chemoradiotherapy.
Park JS; Huh JW; Park YA; Cho YB; Yun SH; Kim HC; Lee WY; Chun HK
Dis Colon Rectum; 2014 Aug; 57(8):933-40. PubMed ID: 25003288
[TBL] [Abstract][Full Text] [Related]
44. The depth of post-treatment perirectal tissue invasion is a predictor of outcome in patients with clinical T3N1M0 rectal cancer treated with neoadjuvant chemoradiation followed by surgical resection.
Brandt WS; Yong S; Abood G; Micetich K; Walther A; Shoup M
Am J Surg; 2014 Mar; 207(3):357-60; discussion 360. PubMed ID: 24456833
[TBL] [Abstract][Full Text] [Related]
45. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade.
Wheeler JM; Dodds E; Warren BF; Cunningham C; George BD; Jones AC; Mortensen NJ
Dis Colon Rectum; 2004 Dec; 47(12):2025-31. PubMed ID: 15657650
[TBL] [Abstract][Full Text] [Related]
46. Oncologic outcomes of pathologic stage I lower rectal cancer with or without preoperative chemoradiotherapy: are they comparable?
Huh JW; Kim CH; Kim HR; Kim YJ
Surgery; 2011 Nov; 150(5):980-4. PubMed ID: 21875732
[TBL] [Abstract][Full Text] [Related]
47. Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer.
Carruthers R; Tho LM; Brown J; Kakumanu S; McCartney E; McDonald AC
Colorectal Dis; 2012 Oct; 14(10):e701-7. PubMed ID: 22731833
[TBL] [Abstract][Full Text] [Related]
48. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer.
Mace AG; Gantt GA; Skacel M; Pai R; Hammel JP; Kalady MF
Dis Colon Rectum; 2013 Nov; 56(11):1217-27. PubMed ID: 24104995
[TBL] [Abstract][Full Text] [Related]
49. Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer.
Valentini V; van Stiphout RG; Lammering G; Gambacorta MA; Barba MC; Bebenek M; Bonnetain F; Bosset JF; Bujko K; Cionini L; Gerard JP; Rödel C; Sainato A; Sauer R; Minsky BD; Collette L; Lambin P
Radiother Oncol; 2015 Mar; 114(3):302-9. PubMed ID: 25716096
[TBL] [Abstract][Full Text] [Related]
50. Session 4: Trying to augment response with chemotherapy: a triumph of hope over experience?
Battersby NJ; Perez RO; Baxter N; Moran B; Brown G
Colorectal Dis; 2018 May; 20 Suppl 1():100-102. PubMed ID: 29878682
[TBL] [Abstract][Full Text] [Related]
51. [Predictive factors for locally recurrent rectal cancer after primary curative surgery].
Gao H; Zhang T; Zhao R
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Nov; 18(11):1176-9. PubMed ID: 26616817
[TBL] [Abstract][Full Text] [Related]
52. Session 3: Many ways to organ preserve the rectum but which is correct?
Read J; Tekkis P; Rullier E; Nicholls J; Mortensen N; Marks J; Steele RJC; Brown G
Colorectal Dis; 2018 May; 20 Suppl 1():82-87. PubMed ID: 29878680
[TBL] [Abstract][Full Text] [Related]
53. A novel approach to inoperable or recurrent rectal cancer by chemoembolization: A new arrow in our quiver?
Bini R; Comelli S; Leli R; Vaudano GP; Savio D; Viora T; Addeo A
Oncotarget; 2016 Jul; 7(29):45275-45282. PubMed ID: 27303924
[TBL] [Abstract][Full Text] [Related]
54. Outcome measures in multimodal rectal cancer trials.
Fokas E; Glynne-Jones R; Appelt A; Beets-Tan R; Beets G; Haustermans K; Marijnen C; Minsky BD; Ludmir E; Quirke P; Sebag-Montefiore D; Garcia-Aguilar J; Gambacorta MA; Valentini V; Buyse M; Rödel C
Lancet Oncol; 2020 May; 21(5):e252-e264. PubMed ID: 32359501
[TBL] [Abstract][Full Text] [Related]
55. Clinicopathological attributes and outcomes of treatment in young-onset rectal cancer.
Damodaran D; Seshadri RA
Int J Colorectal Dis; 2016 Mar; 31(3):757-9. PubMed ID: 26003117
[No Abstract] [Full Text] [Related]
56. Identifying the most predictive post-chemoradiation TRG system for rectal cancer.
Minsky BD; Rodel C
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25249541
[No Abstract] [Full Text] [Related]
57. Repopulation of Rectal Cancer May Explain Worse Local Control After Short-Course Radiation Therapy in the RAPIDO Trial.
Socha J; Bujko K
Dis Colon Rectum; 2024 Mar; 67(3):e204-e205. PubMed ID: 38064232
[No Abstract] [Full Text] [Related]
58. Comment on the editorial of Sautter-Bihl et al. in Strahlentherapie und Onkologie 2013 189:105-110.
Junginger T; Maurer CA; Ruppert R; Ptok H; Strassburg J
Strahlenther Onkol; 2013 Aug; 189(8):697-9. PubMed ID: 23700208
[No Abstract] [Full Text] [Related]
59. Why event-free survival is better than tumor response or other measures of survival as an endpoint in cancer trials.
Dillman RO
Cancer Biother Radiopharm; 1996 Apr; 11(2):99-104. PubMed ID: 10851525
[No Abstract] [Full Text] [Related]
60. Complete pathological and serological response to immunotherapy in a patient with MMR-deficient early rectal cancer.
Tarpgaard LS; Andersen PV; Øgaard N; Demuth C; Andersen CL; Pfeiffer P
Ann Oncol; 2021 Jun; 32(6):805-806. PubMed ID: 33727198
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
